Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen

Doris Apt1, Kanakatte Raviprakash, Alice Brinkman

  • 1Maxygen Inc., Human Therapeutics, 515 Galveston Drive, Redwood City, CA 94063, USA. doris.apt@maxygen.com

Vaccine
|August 30, 2005
PubMed

Related Concept Videos